Castle Biosciences Inc.
CSTL Nasdaq
SEC CIK 1447362
Follow Castle Biosciences
Weekly email: filings, results
Revenue, last quarter
$102.9M
+23.9% vs same quarter last year
Net income
−$4.1M
−718.4% vs same quarter last year
EPS, diluted
−$0.13
−550% vs same quarter last year
Operating cash flow
$19.7M
−12.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $344.2M | −$24.2M |
| FY24 | $332.1M | $18.2M |
| FY23 | $219.8M | −$57.5M |
| FY22 | $137M | −$67.1M |
| FY21 | $94.1M | −$31.3M |
| FY20 | $62.6M | −$10.3M |
| FY19 | $51.9M | - |
| FY18 | $22.8M | −$6.4M |
| FY17 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 79.4% | −12.4% | −7% |
| FY24 | 81.9% | 2.6% | 5.5% |
| FY23 | 79.5% | −30.9% | −26.1% |
| FY22 | 76.6% | −53.2% | −49% |
| FY21 | 83.2% | −42.6% | −33.3% |
| FY20 | 84.5% | −10.4% | −16.4% |
| FY19 | 85.9% | 14.1% | - |
| FY18 | 76.8% | −16.8% | −27.9% |
| FY17 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $28.3M |
| FY24 | $36.5M |
| FY23 | −$19.2M |
| FY22 | −$47.3M |
| FY21 | −$22.5M |
| FY20 | $5.1M |
| FY19 | $6.1M |
| FY18 | −$12.6M |
| FY17 | - |
- Castle Biosciences
- Healthcare median
Show the numbers
| Year | Castle Biosciences | Healthcare median |
|---|---|---|
| FY25 | −7% | −30.6% |
| FY24 | 5.5% | −47% |
| FY23 | −26.1% | −58% |
| FY22 | −49% | −80.4% |
| FY21 | −33.3% | −71.8% |
| FY20 | −16.4% | −62.2% |
| FY19 | - | −46.2% |
| FY18 | −27.9% | −49.6% |
| FY17 | - | −45.9% |